| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 百奥赛图（股票代码：02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地，以专注技术创新、持续新药产出、守护人类健康为使命。基于百奥赛图自主研发并拥有完全独立知识产权的全人抗体RenMice?平台（RenMab?、RenLite?和RenNano?小鼠），将单抗、双抗和纳米抗体开发技术平台、动物体内药效筛选平台、强大的临床开发能力有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发能力。百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发（“千鼠万抗TM”计划），百奥赛图已签署了多项药物合作开发/授权/转让协议并与包括多家MNC在内的数十家企业达成RenMice?平台授权。同时百奥赛图建立了由10项在研药物组成的核心管线，并且我们已就其中多项临床资产与外部合作方建立了项目合作关系。未来，百奥赛图将继续携手全球合作伙伴，持续产出众多抗体药物，更好地惠及患者。百奥赛图总部位于北京，在中国（江苏海门、上海）、美国（波士顿、旧金山）及德国海德堡等地设有分支机构。 我们的使命：专注技术创新，持续新药产出，守护人类健康 我们的愿景：致力于成为全球新药发源地 | ||||||||||||||||||||||||
| Main Business | 公司基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务，并利用其自主开发的RenMice 全人抗体/TCR 小鼠平台（包括RenMab、RenLite、RenNano、RenTCR以及RenTCR-mimic 多个系列）针对人体内千余个潜在药物靶点进行规模化药物发现与开发（以下简称“千鼠万抗”），并将有潜力的抗体分子进行对外转让、授权或合作开发。 | ||||||||||||||||||||||||
| Legal Representative | 沈月雷 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 王永亮 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 毕马威华振会计师事务所 | ||||||||||||||||||||||||
| Tel No | 86-10-56967601 | ||||||||||||||||||||||||
| Fax No | 86-10-56967666-8067 | ||||||||||||||||||||||||
| Website | www.biocytogen.com.cn | ||||||||||||||||||||||||
| ir@bbctg.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/12/2025 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.080 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.090 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.361B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |